This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Equillium's EQUALISE Type B Phase 1b Study of itolizumab in Active Proliferative Lupus Nephritis
Ticker(s): EQWho's the expert?
Institution: UC San Diego
-
Professor of Medicine at UC San Diego; Director, UCSD Lupus Center of Excellence.
-
Chair Steering Committee, Lupus Clinical Investigators Network (LuCIN).
- Research focuses on Prognostic and predictive factors for outcomes and innovative therapies in rheumatic diseases.
Interview GoalThis conversation will discussing the 2023 Itolizumab ACR poster "Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis" with an author.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
